Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide against Malignant Gliomas

PURPOSE: HSP90, a highly conserved molecular chaperone that regulates the function of several oncogenic client proteins is altered in glioblastoma. However, HSP90 inhibitors currently in clinical trials are short-acting, have unacceptable toxicities or are unable to cross the blood brain barrier (BB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Canella, Alessandro, Welker, Alessandra M., Yoo, Ji Young, Xu, Jihong, Abas, Fazly S., Kesanakurti, Divya, Nagarajan, Prabhakaran, Beattie, Christine E., Sulman, Erik P, Liu, Joseph, Gumin, Joy, Lang, Frederick F., Gurcan, Metin N., Kaur, Balveen, Sampath, Deepa, Puduvalli, Vinay K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986078/
https://ncbi.nlm.nih.gov/pubmed/28679777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados